Reid Adler compensation by year
Vistagen Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2025 | FY2026 |
|---|---|---|
| Salary | $450,000 | $450,000 |
| Bonus | $198,450 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $527,357 | $187,520 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $1,175,807 | $637,520 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vistagen Therapeutics, Inc. DEF 14A filed July 31, 2026, accession 0001628280-26-051404, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Vistagen Therapeutics, Inc. filed document, accession 0001628280-26-051404. Every figure is read from that document and cited to the page and table it appears in. Filed July 31, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 276 | — | $38.40 |
| Option | 70,833 | — | $3.23 |
| Option | 75,000 | — | $1.96 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vistagen Therapeutics, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Vistagen Therapeutics’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Shawn Singh | President, Chief Executive Officer and Director | $1,212,560 |
| Nick Tressler | Chief Financial Officer and Treasurer | $866,516 |
| Elissa Cote | Chief Corporate Development and Strategy Officer | $696,134 |
| Reid Adler · this page | Chief Legal Officer | $637,520 |
| Joshua Prince | Chief Operating Officer | $602,520 |
The full Vistagen Therapeutics compensation record
free company briefThis page is one person within Vistagen Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vistagen Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.